CureVac N.V.

-0.02 (-0.04%)
Products, Regulatory

Curevac's CV2CoV Demonstrates Improved Immune Response And Protection In Preclinical Study

Published: 08/16/2021 11:08 GMT
CureVac N.V. (CVAC) - Second-generation Mrna Covid-19 Vaccine Candidate, Cv2cov, Demonstrates Improved Immune Response and Protection in Preclinical Study.
Preclinical Study Provides Evidence for Strongly Improved Immune Responses With Second-generation Mrna Backbone Jointly Developed by Curevac and Gsk Compared to Curevac's First-generation Mrna Backbone.
Following Current Preclinical Development of Cv2cov, a Phase 1 Clinical Trial is Expected to Start in Q4 2021.